Buy Side

Selecting the most appropriate and profitable opportunities for those who buy companies.
Having developed a unique methodological process, the Scape Reports – maps and complex databases of the business ecosystems that drive the tech economy – Pipeline Capital ensures the most accurate opportunity screening process, in addition to, through the knowledge accumulated from years in the markets in which it operates.
Years on the road
+
Billion in market cap value under management
USD 1

Operational offices in Latam, Europe and US

We are prepared to offer the best support and advice for Buy Side customers. The steps below are modular and may follow a different sequence from the one shown.

TECH M&A

Pipeline Capital is not a conventional M&A and Investment company. We understand it as a strategic activity of expansion, development and prosperity of companies in the corporate environment. We act in a senior consultative manner, from briefing to valuation modeling and proposal.

Target Screening Strategic discussion of the company’s paths in the financial vision, geographic expansion, segments and inorganic growth. Our Screening area mixes a series of proprietary methodologies to reach the ideal leads for your Acquisition Thesis. In addition, we apply our Investment Rating, an analysis of the main management pillars, to each asset in the shortlist. Average term: 40 - 60 days

Monitoring and Due Diligence Management When we reach a lead within the thesis, we start following the due diligence. The result is a clear picture of the investment object, an accurate assessment of the company’s financial situation and a study of its activities.
Average term: 60 - 90 days

Closing The diligence results in a report of the company to be acquired and the negotiation process (adjustment) of all terms begins. The signing between the parties represents the project’s success.

The success stories

Our full experience with national and multinational groups, allows us to present a large portfolio in transactions. We always seek the best results for our partners.

What our customers say

Pipeline News

From Fintech to Unicorn: Klarna and Hinge Health Lead the Way in 2025

In a 2025 marked by the consolidation of profitable models and the strategic recovery of many high-growth tech companies, Klarna and Hinge Health have

What happens when you try to sell without knowing your company’s real value

Key risk: selling too cheap or asking above fair value and scaring buyers away We all have a rough idea of how much our

The Hidden Cost of Tariffs: The Impact on Tech M&A in April

In April 2025, the implementation of tariffs introduced by the Trump administration reactivated the global trade war. With massive tariffs — between 10% and